Marta Weinstock-Rosin
Direktor/Vorstandsmitglied bei Avraham Pharmaceuticals Ltd.
Profil
Marta Weinstock-Rosin is the founder of Spero Biopharma Ltd.
She is currently a Director at Avraham Pharmaceuticals Ltd.
and a Professor-Emeritus at The Hebrew University of Jerusalem.
Previously, she served as the President of The Israel Society for Neuroscience from 2005 to 2005.
Aktive Positionen von Marta Weinstock-Rosin
Unternehmen | Position | Beginn |
---|---|---|
Avraham Pharmaceuticals Ltd.
Avraham Pharmaceuticals Ltd. BiotechnologyHealth Technology Avraham Pharmaceuticals Ltd. develops pharmaceutical products for prevention and treatment of neurodegenerative disorders. Its lead product candidate, Ladostigil is designed to provide treatment for Mild Cognitive Impairment. The firm’s product candidate is a multifunctional compound that combines neuroprotective mechanisms: reducing oxidative stress and microglial activation, and inhibiting proinflamtory cytokines. The company was founded in 2010 by David Warshawsky and is headquartered in Yavneh, Israel. | Direktor/Vorstandsmitglied | - |
The Hebrew University of Jerusalem | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Marta Weinstock-Rosin
Unternehmen | Position | Ende |
---|---|---|
The Israel Society for Neuroscience | Präsident | 01.01.2005 |
Spero Biopharma Ltd.
Spero Biopharma Ltd. Pharmaceuticals: MajorHealth Technology Spero Biopharma Ltd. develops ladostigil an treatment for mild cognitive impairment. The company was founded by Marta Weinstock-Rosin and is headquartered in Tel Aviv-Yafo, Israel. | Gründer | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 3 |
---|---|
The Israel Society for Neuroscience | |
Avraham Pharmaceuticals Ltd.
Avraham Pharmaceuticals Ltd. BiotechnologyHealth Technology Avraham Pharmaceuticals Ltd. develops pharmaceutical products for prevention and treatment of neurodegenerative disorders. Its lead product candidate, Ladostigil is designed to provide treatment for Mild Cognitive Impairment. The firm’s product candidate is a multifunctional compound that combines neuroprotective mechanisms: reducing oxidative stress and microglial activation, and inhibiting proinflamtory cytokines. The company was founded in 2010 by David Warshawsky and is headquartered in Yavneh, Israel. | Health Technology |
Spero Biopharma Ltd.
Spero Biopharma Ltd. Pharmaceuticals: MajorHealth Technology Spero Biopharma Ltd. develops ladostigil an treatment for mild cognitive impairment. The company was founded by Marta Weinstock-Rosin and is headquartered in Tel Aviv-Yafo, Israel. | Health Technology |